1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
2. Adjust treatment and monitoring plans as needed based on the pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
3. Devise and communicate appropriate plans for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer including neurotoxicity from ifosfamide and hemorrhagic cystitis.